FR3095340B1 - Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique - Google Patents

Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique Download PDF

Info

Publication number
FR3095340B1
FR3095340B1 FR1904404A FR1904404A FR3095340B1 FR 3095340 B1 FR3095340 B1 FR 3095340B1 FR 1904404 A FR1904404 A FR 1904404A FR 1904404 A FR1904404 A FR 1904404A FR 3095340 B1 FR3095340 B1 FR 3095340B1
Authority
FR
France
Prior art keywords
initial
physico
release
increasing
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1904404A
Other languages
English (en)
Other versions
FR3095340A1 (fr
Inventor
Edouard Alphandéry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphaonco SAS
Original Assignee
Nanobacterie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobacterie filed Critical Nanobacterie
Priority to FR1904404A priority Critical patent/FR3095340B1/fr
Priority to CA3136792A priority patent/CA3136792C/fr
Priority to US17/605,383 priority patent/US20220233723A1/en
Priority to EP20721811.6A priority patent/EP3958836A1/fr
Priority to PCT/IB2020/053854 priority patent/WO2020217205A1/fr
Publication of FR3095340A1 publication Critical patent/FR3095340A1/fr
Application granted granted Critical
Publication of FR3095340B1 publication Critical patent/FR3095340B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé pour augmenter la libération d'au moins un composé, ledit composé étant initialement un composé initial lié à au moins une nanoparticule initiale, ledit composé initial lié à ladite nanoparticule initiale formant une particule initiale, la particule initiale comprenant au moins un principe actif, ledit procédé comprenant au moins une étape d'altération de la particule initiale et au moins une étape de perturbation physico-chimique d'une particule altérée résultant de l'étape précédente. (Figure 7).
FR1904404A 2019-04-25 2019-04-25 Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique Active FR3095340B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1904404A FR3095340B1 (fr) 2019-04-25 2019-04-25 Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique
CA3136792A CA3136792C (fr) 2019-04-25 2020-04-23 Procede permettant d'augmenter la liberation de composes medicaux presents dans des nanoparticules par une etape de modification et une etape de perturbation physico-chimique
US17/605,383 US20220233723A1 (en) 2019-04-25 2020-04-23 Method for increasing the release of medical compounds from nanoparticles by an alteration step and a physico-chemical disturbance step
EP20721811.6A EP3958836A1 (fr) 2019-04-25 2020-04-23 Procédé permettant d'augmenter la libération de composés médicaux présents dans des nanoparticules par une étape de modification et une étape de perturbation physico-chimique
PCT/IB2020/053854 WO2020217205A1 (fr) 2019-04-25 2020-04-23 Procédé permettant d'augmenter la libération de composés médicaux présents dans des nanoparticules par une étape de modification et une étape de perturbation physico-chimique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1904404 2019-04-25
FR1904404A FR3095340B1 (fr) 2019-04-25 2019-04-25 Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique

Publications (2)

Publication Number Publication Date
FR3095340A1 FR3095340A1 (fr) 2020-10-30
FR3095340B1 true FR3095340B1 (fr) 2023-06-09

Family

ID=67956980

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1904404A Active FR3095340B1 (fr) 2019-04-25 2019-04-25 Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique

Country Status (4)

Country Link
US (1) US20220233723A1 (fr)
EP (1) EP3958836A1 (fr)
FR (1) FR3095340B1 (fr)
WO (1) WO2020217205A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061259A1 (fr) * 2009-11-18 2011-05-26 Nanobacterie Traitement de cancer ou de tumeurs induit par la libération de chaleur générée par différentes chaînes de magnétosomes extraites de bactéries magnétotactiques et soumises à un champ magnétique alternatif
FR3042874A1 (fr) 2015-10-21 2017-04-28 Nanobacterie Particule comprenant au moins une particule d'oxyde de fer ferrimagnetique associee a au moins un compose pour une utilisation medicale ou cosmetique

Also Published As

Publication number Publication date
WO2020217205A1 (fr) 2020-10-29
CA3136792A1 (fr) 2020-10-29
FR3095340A1 (fr) 2020-10-30
US20220233723A1 (en) 2022-07-28
EP3958836A1 (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
JP2019094340A5 (fr)
Liu et al. Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions
Mishra et al. Imidazole as an anti-epileptic: an overview
EP3587422A4 (fr) Composé dérivé de pyrrolo-pyrimidine, son procédé de préparation, et composition pharmaceutique comprenant ledit composé en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la protéine kinase
EP4053122A4 (fr) Composé comprenant un inhibiteur d'ezh2 et un liant de ligase e3 et composition pharmaceutique pour prévenir ou traiter une maladie associée à ezh2 comprenant celui-ci en tant que principe actif
D'Amour et al. Interictal spike frequency varies with ovarian cycle stage in a rat model of epilepsy
ATE348524T1 (de) Mikrobizide formulierung die essentielle öle oder deren derivate enthält
FR2999956B1 (fr) Nano-catalyseurs metalliques dans le glycerol et applications en synthese organique
EP3801378A4 (fr) Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
Ryskalin et al. Neuroprotective effects of curcumin in methamphetamine-induced toxicity
FR3095340B1 (fr) Procede d'augmentation de la liberation de composes medicaux de nanoparticules apres une etape d’altération et une etape de perturbation physico-chimique
MA39894B1 (fr) Procede de transport et/ou de stockage de bitume routier
Caito et al. Dopaminergic neurotoxicity of S‐ethyl N, N‐dipropylthiocarbamate (EPTC), molinate, and S‐methyl‐N, N‐diethylthiocarbamate (Me DETC) in C aenorhabditis elegans
Tan et al. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth
Soares et al. Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans
EP3395804A4 (fr) Nouveau composé dérivé de spiroquinone, son procédé de production, et composition pharmaceutique le contenant en tant que principe actif pour prévenir ou traiter des troubles neurologiques
Pomel et al. Antiprotozoal activity of ferroquine
Golko-Perez et al. Additive neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis
Bayrak et al. The protective effect of vitamin U on pentylenetetrazole‐induced brain damage in rats
WO2011031816A3 (fr) Agonistes inverses et antagonistes du récepteur h3 de l'histamine et leurs procédés d'utilisation
Salinas-Castillo et al. Sensitive and simple determination of the vasodilator agent dipyridamole in pharmaceutical preparations by phosphorimetry
ITMI20120356A1 (it) Stampo di tranciatura con dispositivo di frenatura antigrippaggio
Chopde et al. Synthesis, Characterization, Antibacterial, and Antifungal Activity of Novel 2‐(2‐hydroxy‐5‐((aryl)‐diazenyl) phenyl)‐3‐(4‐hydroxyphenyl)‐thiazolidin‐4‐one
Hollywood et al. The PI‐PLC inhibitor U‐73122 is a potent inhibitor of the SERCA pump in smooth muscle
Kebriaeezadeh et al. Anticonvulsant and antiepileptogenic effects of azolylchromanones on lithium–pilocarpine induced seizures and pentylenetetrazole-kindling model of epilepsy

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201030

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7